Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total revenues	$ 34,470	$ 36,769	$ 108,215	$ 80,253
Cost of product revenue	9,786	6,867	29,577	15,403
Research and development	21,821	15,165	60,410	39,562
Selling, general and administrative	13,499	13,407	39,859	37,600
Total costs and operating expenses	45,106	35,439	129,846	92,565
Income (loss) from operations	(10,636)	1,330	(21,631)	(12,312)
Unallocated depreciation and amortization	(1,405)	(768)	(3,961)	(2,143)
Stock-based compensation	4,531	3,016	11,600	8,547
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	31,146	32,584	100,774	68,397
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,324	4,185	7,441	11,856
Product revenue
Segment Reporting Information [Line Items]
Total revenues	28,042	28,731	93,376	53,674
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	28,042	28,731	93,376	53,674
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	6,428	8,038	14,839	26,579
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	3,104	3,853	7,398	14,723
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,324	4,185	7,441	11,856
Operating segments
Segment Reporting Information [Line Items]
Total revenues	34,470	36,769	108,215	80,253
Cost of product revenue	9,786	6,867	29,577	15,403
Research and development	20,637	14,520	57,112	37,821
Selling, general and administrative	4,679	4,137	13,496	11,346
Total costs and operating expenses	35,102	25,524	100,185	64,570
Income (loss) from operations	(632)	11,245	8,030	15,683
Stock-based compensation	4,531	3,016	11,600	8,547
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	31,146	32,584	100,774	68,397
Cost of product revenue	9,786	6,867	29,577	15,403
Research and development	6,782	5,670	19,833	17,172
Selling, general and administrative	3,791	3,306	11,208	9,294
Total costs and operating expenses	20,359	15,843	60,618	41,869
Income (loss) from operations	10,787	16,741	40,156	26,528
Stock-based compensation	1,382	1,228	4,151	3,337
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,324	4,185	7,441	11,856
Cost of product revenue	0	0	0	0
Research and development	13,855	8,850	37,279	20,649
Selling, general and administrative	888	831	2,288	2,052
Total costs and operating expenses	14,743	9,681	39,567	22,701
Income (loss) from operations	(11,419)	(5,496)	(32,126)	(10,845)
Stock-based compensation	414	272	1,182	767
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	28,042	28,731	93,376	53,674
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	6,428	8,038	14,839	26,579
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(7,947)	(8,097)	(24,940)	(24,431)
Unallocated depreciation and amortization	(1,405)	(794)	(3,953)	(2,220)
Income (loss) before income taxes	(9,984)	2,354	(20,863)	(10,968)
Stock-based compensation	$ 2,735	$ 1,516	$ 6,267	$ 4,443